Does Lexapro cause gynaecomastia? This is a question increasingly raised by men prescribed escitalopram — sold in the UK as Cipralex — for depression or anxiety. Gynaecomastia, the benign enlargement of glandular breast tissue in males, has been reported in association with several antidepressants, including SSRIs. However, gynaecomastia is not listed as a recognised adverse effect in the MHRA-approved Summary of Product Characteristics for escitalopram, nor in EMA product information. Individual case reports suggest a possible but unconfirmed link. This article explores the evidence, the theoretical mechanisms involved, and what to do if you notice breast changes whilst taking escitalopram.

Can Escitalopram (Cipralex) Cause Gynaecomastia?

Gynaecomastia is not listed as a recognised adverse effect in the MHRA-approved SmPC or EMA product information for escitalopram; it should be regarded as a rare, unconfirmed potential association rather than an expected side effect.

Escitalopram is a selective serotonin reuptake inhibitor (SSRI) widely prescribed in the UK for depression and generalised anxiety disorder, most commonly dispensed under the brand name Cipralex. In some other countries it is marketed as Lexapro, though the active compound is identical. Escitalopram is among the more frequently prescribed antidepressants in UK primary care, making questions about its side-effect profile particularly relevant to patients and clinicians alike.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — has been reported in association with several antidepressant medications, including SSRIs. However, it is important to note that gynaecomastia is not listed as an adverse reaction in the UK Summary of Product Characteristics (SmPC) for Cipralex (escitalopram), as approved by the MHRA and available via the Electronic Medicines Compendium (EMC). This position is consistent with the European Medicines Agency (EMA) product information for escitalopram-containing medicines, which likewise does not include gynaecomastia as a recognised adverse effect.

Individual case reports and pharmacovigilance data do suggest a possible association between SSRI use and gynaecomastia in some men, but this association remains unconfirmed by large-scale clinical evidence. Based on available data, gynaecomastia should be regarded as a rare and unconfirmed potential adverse effect of escitalopram rather than a recognised or expected one. The relationship is likely influenced by individual hormonal sensitivity, concurrent medications, and underlying health conditions.

If you notice breast tissue swelling or tenderness whilst taking escitalopram, do not stop the medication abruptly. Seek prompt advice from your GP or pharmacist, who can assess your symptoms and advise on next steps.

How SSRIs May Theoretically Affect Hormone Levels in Men

SSRIs can theoretically raise prolactin via serotonergic stimulation of the pituitary, potentially suppressing testosterone and shifting the oestrogen-to-androgen ratio, but this causal chain remains unestablished for escitalopram.

To understand why SSRIs such as escitalopram might theoretically contribute to gynaecomastia in rare cases, it is helpful to consider their pharmacological mechanism. SSRIs work by blocking the reuptake of serotonin in the synaptic cleft, thereby increasing serotonergic neurotransmission. This action is primarily central, but serotonin also plays a modulatory role in the hypothalamic–pituitary axis, which governs the release of reproductive hormones.

Elevated serotonin activity can, in theory, stimulate the release of prolactin from the anterior pituitary gland — a phenomenon known as hyperprolactinaemia. Hyperprolactinaemia and galactorrhoea have been rarely reported with SSRIs as a class. Prolactin, when elevated, may suppress testosterone production and alter the oestrogen-to-testosterone ratio. Since gynaecomastia fundamentally arises from an imbalance between oestrogen and androgen activity in breast tissue, any drug that disrupts this balance could theoretically promote breast tissue growth in susceptible individuals. It should be emphasised that this mechanistic pathway remains theoretical for SSRIs and does not represent an established causal chain.

This hormonal effect is more strongly and consistently associated with antipsychotic medications — particularly those that block dopamine D2 receptors, which normally inhibit prolactin release — than with SSRIs. Gynaecomastia is multifactorial in origin, and other contributors may include weight gain (which increases peripheral aromatisation of androgens to oestrogens), liver disease (which impairs oestrogen metabolism), and hypogonadism. In men who already have borderline hormonal profiles, even a modest shift in hormone balance may be clinically significant, regardless of cause. NICE CKS guidance on gynaecomastia provides a useful overview of the pathophysiology and contributing factors relevant to UK primary care.

How Common Is Gynaecomastia With Escitalopram?

Gynaecomastia was not identified in pivotal clinical trials for escitalopram and is not listed in its product information; Yellow Card reports exist but cannot confirm causality.

Accurately quantifying the incidence of gynaecomastia specifically attributable to escitalopram is challenging. Gynaecomastia itself is common in the general male population at various life stages — particularly during puberty and older age — and is caused by a wide range of factors including ageing, obesity, alcohol use, and numerous medications. NICE CKS guidance on gynaecomastia notes its prevalence across these life stages.

Gynaecomastia is not listed in the MHRA/EMC SmPC or EMA product information for escitalopram, and it was not identified as an adverse event in the pivotal clinical trials supporting its licence. Gynaecomastia has been reported via the MHRA Yellow Card scheme in association with escitalopram, but spontaneous reporting systems are subject to under-reporting and cannot establish causality. These reports should be interpreted with caution.

By contrast, other medications more commonly implicated in drug-induced gynaecomastia include (as examples, not an exhaustive list):

• Spironolactone (an aldosterone antagonist)

• Cimetidine (a histamine H2 blocker)

• Anabolic steroids and exogenous testosterone

• Antipsychotics such as haloperidol and risperidone

• Antiandrogens and some prostate cancer treatments (e.g., bicalutamide, finasteride)

If a man taking escitalopram develops gynaecomastia, a thorough medication review — including over-the-counter medicines and supplements — is essential to identify all potential contributing agents before attributing the symptom to the antidepressant alone.

When to Speak to Your GP or Pharmacist

Men should contact their GP promptly for any new breast swelling, hard or irregular lump, nipple discharge, or skin changes; NICE NG12 supports urgent two-week-wait referral if malignancy is suspected.

Any new or unexplained breast swelling, tenderness, or nipple discharge in a male patient warrants prompt medical evaluation, regardless of current medication use. Whilst drug-induced gynaecomastia is generally benign and potentially reversible, it is important to rule out other causes — including, in rare cases, male breast cancer, which accounts for approximately 1% of all breast cancer diagnoses in the UK.

You should contact your GP if you experience:

• Visible or palpable breast tissue enlargement that is new or worsening

• Breast pain or tenderness that is persistent

• Nipple discharge, particularly if bloodstained

• A hard, irregular, or fixed lump in the breast area

• Skin changes over the breast, such as dimpling, puckering, or redness

• Unilateral (one-sided) swelling, which is more likely to require investigation than bilateral changes

In line with NICE NG12 (Suspected Cancer: Recognition and Referral), GPs should consider an urgent two-week-wait referral for men with breast symptoms that raise suspicion of malignancy — for example, a unilateral, hard, or irregular lump, skin or nipple changes, or bloodstained nipple discharge. If you are concerned about any of these features, seek medical advice promptly rather than waiting.

Your GP will typically take a full medication history and perform a clinical examination, including assessment of the testes (as testicular pathology can cause gynaecomastia). They may arrange baseline blood tests including serum testosterone, oestradiol, prolactin, LH, FSH, thyroid function tests (TFTs), beta-hCG (if malignancy is suspected), liver function tests, and renal profile. Testicular ultrasound may be arranged if a testicular mass is identified or suspected. It is also worth noting the clinical distinction between true gynaecomastia — which involves firm, glandular, subareolar tissue — and pseudogynaecomastia, which is fatty tissue without glandular proliferation and does not carry the same clinical implications.

Do not stop taking escitalopram without medical guidance, as abrupt discontinuation can cause discontinuation symptoms and may destabilise your mental health. Your GP can advise on whether watchful waiting, dose adjustment, or a medication switch is most appropriate.

Managing Gynaecomastia While Taking Antidepressants

Management options include watchful waiting for up to 6–12 months in mild cases, medication review with possible switching guided by SPS guidance, addressing modifiable risk factors, and referral if symptoms persist or cause significant distress.

If gynaecomastia is suspected to be related to escitalopram or another antidepressant, management will depend on the severity of symptoms, the degree of certainty about causation, and the clinical importance of continuing antidepressant treatment. In many cases, the mental health benefits of continuing effective antidepressant therapy will outweigh the discomfort of mild gynaecomastia, particularly if the breast changes are minor.

Practical management options may include:

• Watchful waiting: Mild gynaecomastia may resolve spontaneously, particularly if it develops early in treatment. NICE CKS guidance suggests an observation period of up to 6–12 months is reasonable in mild cases. It is important to note that long-standing gynaecomastia (typically beyond 12 months) may become fibrotic and is less likely to regress, which informs the timing of referral decisions.

• Medication review: Your GP may consider switching to an antidepressant with a different pharmacological profile if the association seems likely and symptoms are troublesome. The appropriate switching strategy depends on the specific drugs involved and individual patient factors. Switching between antidepressants is not always achieved by gradual cross-tapering; in some cases a direct switch is more appropriate, whilst in others a washout period may be needed. Clinicians should follow current UK Specialist Pharmacy Service (SPS) guidance on switching antidepressants, as strategies vary and inappropriate cross-tapering carries a risk of serotonin syndrome.

• Addressing contributing factors: Reducing alcohol intake, achieving a healthy body weight, and reviewing all other medications (including over-the-counter supplements) can help address modifiable risk factors.

• Referral: NICE CKS guidance on gynaecomastia supports referral to endocrinology or surgery when there is diagnostic uncertainty, abnormal hormone results, symptoms persisting beyond 12 months, significant pain, or significant psychological distress. Surgical referral may be appropriate for established, fibrotic gynaecomastia that has not responded to conservative measures.

Psychological support should not be overlooked. Gynaecomastia can cause significant embarrassment and distress, and this should be acknowledged sensitively in consultations.

MHRA Guidance and Reporting Side Effects in the UK

The MHRA Yellow Card scheme allows patients and clinicians to report suspected adverse reactions to escitalopram; gynaecomastia is not currently listed in the MHRA-approved or EMA product information for escitalopram.

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for monitoring the safety of all licensed medicines, including escitalopram. The MHRA operates the Yellow Card scheme, which allows both healthcare professionals and members of the public to report suspected adverse drug reactions (ADRs). This voluntary reporting system plays a vital role in post-marketing surveillance and helps identify rare or previously unrecognised side effects that may not have been apparent during clinical trials.

If you believe you have experienced gynaecomastia or any other unexpected side effect whilst taking escitalopram, you are encouraged to report it via the Yellow Card website (yellowcard.mhra.gov.uk) or through the Yellow Card app. Reports from patients are valued equally alongside those from clinicians and contribute directly to ongoing safety assessments.

The EMA has reviewed the safety profile of escitalopram-containing products, and its product information — consistent with the MHRA-approved SmPC for Cipralex in the UK — does not list gynaecomastia as a recognised adverse effect. Clinicians wishing to review the full adverse effect profile of escitalopram should consult the current SmPC via the EMC (medicines.org.uk) and the BNF (NICE).

Healthcare professionals should remain vigilant and maintain an open dialogue with patients about unexpected physical changes during antidepressant therapy. Transparent communication, combined with a structured approach to investigation and reporting, ensures that both individual patient safety and broader public health surveillance are upheld to the highest standard.

Frequently Asked Questions